← Leaderboards
Douglas M McCarty
University Of North Carolina Chapel Hill
$10,391,159
Attributed
$10,917,455
Total exposure
11
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,917,455 · 11
By mechanism
R44$5,538,061 · 3
R01$2,901,990 · 3
R41$1,052,593 · 2
P30$765,268 · 1
R21$393,759 · 1
P01$265,784 · 1
Top collaborators
- Haiyan Fu3 shared
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Haiyan Fu$5,284,175
- Joseph J. Muenzer$1,130,475
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyVectorAdeno-Associated Viral VectorRecombinant Adeno-Associated Virus (Raav)Gene DeliveryCellsMouse ModelSafetyTransgenesLysosomal Storage DiseasesTransduction EfficiencyRecombinantsLeadDoseViral VectorToxic EffectMissionTissuesSuccessFamilyBlood - Brain Barrier AnatomyTechnologyProductionClinically Relevant
Grant awards (31)
Trans-BBB AAV9 gene therapy targeting CNS neuropathy of MPS I$1,499,504
R44 · FY2025 · NS · contact PI
Development of gene therapy product for treating MPS IIIB$1,305,826
R44 · FY2025 · NS · contact PI
Protein depleting pre-existing antibodies for viral gene therapy$969,817
R44 · FY2025 · AI · contact PI
Novel AAV gene therapy for treating CNS neuropathy of MPS IIIC$349,909
R41 · FY2025 · NS
Protein depleting pre-existing antibodies for viral gene therapy$1,000,000
R44 · FY2024 · AI · contact PI
Development of gene therapy product for treating MPS IIIB$456,414
R44 · FY2024 · NS · contact PI
Develop AAV9 gene replacement therapy for treating MPS I$323,802
R41 · FY2023 · NS
Protein depleting pre-existing antibodies for viral gene therapy$306,500
R44 · FY2023 · AI · contact PI
Develop AAV9 gene replacement therapy for treating MPS I$378,882
R41 · FY2022 · NS
PATTERNS OF r AAV VECTOR INSERTION ASSOCIATED WITH LIVER TUMORS IN A MOUSE MODEL$25,683
R01 · FY2017 · CA · contact PI
PATTERNS OF r AAV VECTOR INSERTION ASSOCIATED WITH LIVER TUMORS IN A MOUSE MODEL$303,988
R01 · FY2016 · CA · contact PI
PATTERNS OF r AAV VECTOR INSERTION ASSOCIATED WITH LIVER TUMORS IN A MOUSE MODEL$303,988
R01 · FY2015 · CA · contact PI
PATTERNS OF r AAV VECTOR INSERTION ASSOCIATED WITH LIVER TUMORS IN A MOUSE MODEL$294,868
R01 · FY2014 · CA · contact PI
PATTERNS OF r AAV VECTOR INSERTION ASSOCIATED WITH LIVER TUMORS IN A MOUSE MODEL$303,988
R01 · FY2013 · CA · contact PI
Self-complementary rAAV9 Systemic Gene Delivery Treatment for MPS Type IIIA$175,509
R21 · FY2013 · NS · contact PI
Self-complementary rAAV9 Systemic Gene Delivery Treatment for MPS Type IIIA$218,250
R21 · FY2012 · NS · contact PI
Recombinant AAV Gene Therapy Vector Recombination, Integration, and Genotoxicity$304,340
R01 · FY2009 · AI · contact PI
Recombinant AAV Gene Therapy Vector Recombination, Integration, and Genotoxicity$304,340
R01 · FY2008 · AI · contact PI
Core--Vector$159,800
P30 · FY2008 · DK · contact PI
Recombinant AAV Gene Therapy Vector Recombination, Integration, and Genotoxicity$310,235
R01 · FY2007 · AI · contact PI
Core--Vector$141,478
P30 · FY2007 · DK · contact PI
Recombinant AAV Gene Therapy Vector Recombination, Integration, and Genotoxicity$319,500
R01 · FY2006 · AI · contact PI
Core--Vector$150,380
P30 · FY2006 · DK · contact PI
Core--Vector$150,380
P30 · FY2005 · DK
Self Complementary Recombinant AAV Vectors$142,000
R01 · FY2005 · AI
Core--Vector$163,230
P30 · FY2004 · DK
Self Complementary Recombinant AAV Vectors$104,383
R01 · FY2004 · AI
Self Complementary Recombinant AAV Vectors$38,761
R01 · FY2004 · AI
Self Complementary Recombinant AAV Vectors$145,916
R01 · FY2003 · AI
Core--Vector$265,784
P01 · FY2002 · HL
Core--Vector$0
P01 · FY2001 · HL